GB virus type C E2 protein inhibits human immunodeficiency virus type 1 assembly through interference with HIV-1 gag plasma membrane targeting

Journal of Infectious Diseases

Volumn 207, Issue 7, 2013, Pages 1171-1180

  Timmons, Christine L ^a   Shao, Qiujia ^a   Wang, Chenliang ^a,b   Liu, Ling ^a   Liu, Huanliang ^b   Dong, Xinhong ^a   Liu, Bindong ^a  

^a MEHARRY MEDICAL COLLEGE   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

GBV C; GBV C E2; HIV 1; HIV 1 assembly; HIV 1 Gag; plasma membrane targeting

Indexed keywords

CAP24 PROTEIN; GAG PROTEIN; GLYCOPROTEIN E2; MAP17 PROTEIN; PR55 PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; CELL COMPARTMENTALIZATION; CELL MEMBRANE; CELL MEMBRANE TRANSPORT; CENTRIFUGATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; HEPATITIS G VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOFLUORESCENCE MICROSCOPY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; PROTEIN SECRETION; PROTEIN TARGETING; PROTEIN TRANSPORT; VIRUS ASSEMBLY; VIRUS CELL INTERACTION; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS REPLICATION; WESTERN BLOTTING;

CD4 LYMPHOCYTE COUNT; CELL MEMBRANE; COINFECTION; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GB VIRUS C; GLYCOSYLATION; HEK293 CELLS; HELA CELLS; HIV INFECTIONS; HIV-1; HUMANS; PLASMIDS; PROTEIN STRUCTURE, TERTIARY; PROTEIN TRANSPORT; TRANSFECTION; VIRAL ENVELOPE PROTEINS; VIRAL LOAD; VIRUS ASSEMBLY; VIRUS RELEASE;

EID: 84874714409     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit001     Document Type: Article

References (50)

1. Simons JN, Desai SM, Schultz DE, Lemon SM, Mushahwar IK. Translation initiation in GB viruses A and C: evidence for internal ribosome entry and implications for genome organization. J Virol 1996; 70:6126-35. (Pubitemid 26266829)
2. Fogeda M, Navas S, Martin J, et al. In vitro infection of human peripheral blood mononuclear cells by GB virus C/hepatitis G virus. J Virol 1999; 73:4052-61. (Pubitemid 29189850)
3. Xiang J, Wunschmann S, Schmidt W, Shao J, Stapleton JT. Full-length GB virus C (hepatitis G virus) RNA transcripts are infectious in primary CD4-positive T cells. J Virol 2000; 74:9125-33.
4. Xiang J, Wunschmann S, Diekema DJ, et al. Effect of coinfection with GB virus C on survival among patients with HIV infection. N Engl J Med 2001; 345:707-14.
5. Stapleton JT. GB virus type C/Hepatitis G virus. Semin Liver Dis 2003; 23:137-48. (Pubitemid 36666683)
6. Heringlake S, Ockenga J, Tillmann HL, et al. GB virus C/hepatitis G virus infection: a favorable prognostic factor in human immunodeficiency virus-infected patients? J Infect Dis 1998; 177:1723-6. (Pubitemid 28243603)
7. Toyoda H, Fukuda Y, Hayakawa T, Takamatsu J, Saito H. Effect of GB virus C/hepatitis G virus coinfection on the course of HIV infection in hemophilia patients in Japan. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17:209-13.
8. Lefrere JJ, Roudot-Thoraval F, Morand-Joubert L, et al. Carriage of GB virus C/hepatitis G virus RNA is associated with a slower immunologic, virologic, and clinical progression of human immunodeficiency virus disease in coinfected persons. J Infect Dis 1999; 179:783-9. (Pubitemid 29159322)
9. Yeo AE, Matsumoto A, Hisada M, Shih JW, Alter HJ, Goedert JJ. Effect of hepatitis G virus infection on progression of HIV infection in patients with hemophilia. Multicenter Hemophilia Cohort Study. Ann Intern Med 2000; 132:959-63. (Pubitemid 30397596)
10. Tillmann HL, Heiken H, Knapik-Botor A, et al. Infection with GB virus C and reduced mortality among HIV-infected patients. N Engl J Med 2001; 345:715-24.
11. Takamatsu J, Toyoda H, Fukuda Y. GB virus C and mortality from HIV infection. N Engl J Med 2002; 346:377-9.
12. Nunnari G, Nigro L, Palermo F, et al. Slower progression of HIV-1 infection in persons with GB virus C co-infection correlates with an intact T-helper 1 cytokine profile. Ann Intern Med 2003; 139:26-30.
13. Xiang J, George SL, Wunschmann S, Chang Q, Klinzman D, Stapleton JT. Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1. Lancet 2004; 363:2040-6. (Pubitemid 38781104)
14. Jung Sa, Knauer Oa, Donhauser Na, et al. Inhibition of HIV strains by GB virus C in cell culture can be mediated by CD4 and CD8 T-lymphocyte derived soluble factors. AIDS 2005; 19:1267-72.
15. Xiang J, McLinden JH, Chang Q, Kaufman TM, Stapleton JT. An 85- aa segment of the GB virus type C NS5A phosphoprotein inhibits HIV-1 replication in CD4+ Jurkat T cells. Proc Natl Acad Sci U S A 2006; 103:15570-5. (Pubitemid 44625633)
16. Chang Q, McLinden JH, Stapleton JT, Sathar MA, Xiang J. Expression of GB virus C NS5A protein from genotypes 1, 2, 3 and 5 and a 30 aa NS5A fragment inhibit human immunodeficiency virus type 1 replication in a CD4+ T-lymphocyte cell line. J Gen Virol 2007; 88:3341-6. (Pubitemid 350201845)
17. Xiang J, McLinden JH, Chang Q, Jordan EL, Stapleton JT. Characterization of a peptide domain within the GB virus C NS5A phosphoprotein that inhibits HIV replication. PLoS One 2008; 3:e2580.
18. Jung S, Eichenmuller M, Donhauser N, et al. HIV entry inhibition by the envelope 2 glycoprotein of GB virus C. AIDS 2007; 21:645-7.
19. Herrera E, Gomara MJ, Mazzini S, Ragg E, Haro I. Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide. J Phys Chem B 2009; 113:7383-91.
20. Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H. Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition. J Virol 2011; 85:7037-47.
21. Mohr EL, Xiang J, McLinden JH, et al. GB virus type C envelope protein E2 elicits antibodies that react with a cellular antigen on HIV- 1 particles and neutralize diverse HIV-1 isolates. J Immunol 2010; 185:4496-505.
22. Xiang J, McLinden JH, Kaufman TM, et al. Characterization of a peptide domain within the GB virus C envelope glycoprotein (E2) that inhibits HIV replication. Virology 2012; 430:53-62.
23. George SL, Varmaz D, Tavis JE, Chowdhury A. The GB virus C (GBV-C) NS3 serine protease inhibits HIV-1 replication in a CD4+ T lymphocyte cell line without decreasing HIV receptor expression. PLoS One 2012; 7:e30653.
24. Freed EO. HIV-1 gag proteins: diverse functions in the virus life cycle. Virology 1998; 251:1-15. (Pubitemid 28527713)
25. Scarlata S, Carter C. Role of HIV-1 Gag domains in viral assembly. Biochim Biophys Acta 2003; 1614:62-72. (Pubitemid 36851603)
26. Ono A. HIV-1 assembly at the plasma membrane: gag trafficking and localization. Future Virol 2009; 4:241-57.
27. Yuan X, Yu X, Lee TH, Essex M. Mutations in the N-terminal region of human immunodeficiency virus type 1 matrix protein block intracellular transport of the Gag precursor. J Virol 1993; 67:6387-94. (Pubitemid 23309102)
28. Zhou W, Parent LJ, Wills JW, Resh MD. Identification of a membrane- binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids. J Virol 1994; 68:2556-69.
29. Bryant M, Ratner L. Myristoylation-dependent replication and assembly of human immunodeficiency virus 1. Proc Natl Acad Sci U S A 1990; 87:523-7.
30. Spearman P, Wang JJ, Vander Heyden N, Ratner L. Identification of human immunodeficiency virus type 1 Gag protein domains essential to membrane binding and particle assembly. J Virol 1994; 68:3232-42. (Pubitemid 24129773)
31. Dunn BM, Goodenow MM, Gustchina A, Wlodawer A. Retroviral proteases. Genome Biol 2002; 3:REVIEWS3006.
32. Wheeler CJ, Felgner PL, Tsai YJ, et al. A novel cationic lipid greatly enhances plasmid DNA delivery and expression in mouse lung. Proc Natl Acad Sci U S A 1996; 93:11454-9. (Pubitemid 26347142)
33. Luo K, Liu B, Xiao Z, et al. Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J Virol 2004; 78:11841-52. (Pubitemid 39390771)
34. Adachi A, Gendelman HE, Koenig S, et al. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986; 59:284-91. (Pubitemid 16013975)
35. Soares MA, Robertson DL, Hui H, Allan JS, Shaw GM, Hahn BH. A full-length and replication-competent proviral clone of SIVAGM from tantalus monkeys. Virology 1997; 228:394-9. (Pubitemid 27238808)
36. Urisman A, Molinaro RJ, Fischer N, et al. Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog 2006; 2:e25.
37. Chesebro B, Wehrly K, Nishio J, Perryman S. Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with Tcell- tropic isolates: definition of critical amino acids involved in cell tropism. J Virol 1992; 66:6547-54.
38. Varthakavi V, Browning PJ, Spearman P. Human immunodeficiency virus replication in a primary effusion lymphoma cell line stimulates lytic-phase replication of Kaposi's sarcoma-associated herpesvirus. J Virol 1999; 73:10329-38.
39. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 1998; 72:2855-64. (Pubitemid 28175522)
40. Wang Y, Shao Q, Yu X, Kong W, Hildreth JE, Liu B. N-terminal hemagglutinin tag renders lysine-deficient APOBEC3G resistant to HIV-1 Vif-induced degradation by reduced polyubiquitination. J Virol 2011; 85:4510-9.
41. Shao Q, Wang Y, Hildreth JE, Liu B. Polyubiquitination of APOBEC3G is essential for its degradation by HIV-1 Vif. J Virol 2010; 84:4840-4.
42. Ono A, Freed EO. Binding of human immunodeficiency virus type 1 Gag to membrane: role of the matrix amino terminus. J Virol 1999; 73:4136-44. (Pubitemid 29189859)
43. Dong X, Li H, Derdowski A, et al. AP-3 directs the intracellular trafficking of HIV-1 Gag and plays a key role in particle assembly. Cell 2005; 120:663-74. (Pubitemid 40343078)
44. Casas J, Espina M, Haro M, et al. Interfacial properties of a synthetic peptide derived from hepatitis G virus E2 protein: interaction with lipid monolayers. Langmuir 2006; 22:246-54. (Pubitemid 43063545)
45. Larios C, Casas J, Alsina MA, Mestres C, Gomara MJ, Haro I. Characterization of a putative fusogenic sequence in the E2 hepatitis G virus protein. Arch Biochem Biophys 2005; 442:149-59. (Pubitemid 41463705)
46. Perez-Lopez S, Nieto-Suarez M, Mestres C, Alsina MA, Haro I, Vila-Romeu N. Behaviour of a peptide sequence from the GB virus C/ hepatitis G virus E2 protein in Langmuir monolayers: its interaction with phospholipid membrane models. Biophys Chem 2009; 141: 153-61.
47. Pilot-Matias TJ, Carrick RJ, Coleman PF, et al. Expression of the GB virus C E2 glycoprotein using the Semliki Forest virus vector system and its utility as a serologic marker. Virology 1996; 225:282-92. (Pubitemid 26392249)
48. Bhattarai N, Stapleton JT. GB virus C: the good boy virus? Trends Microbiol 2012; 20(3):124-30.
49. Joshi A, Garg H, Nagashima K, Bonifacino JS, Freed EO. GGA and Arf proteins modulate retrovirus assembly and release. Mol Cell 2008; 30:227-38. (Pubitemid 351626691)
50. Ono A, Ablan SD, Lockett SJ, Nagashima K, Freed EO. Phosphatidylinositol (4,5) bisphosphate regulates HIV-1 Gag targeting to the plasma membrane. Proc Natl Acad Sci U S A 2004; 101:14889-94. (Pubitemid 39410770)